Table 6.
Patients’ characteristics stratified by Copy number alternation of PIC3CA
| Variable | Copy number of PIK3CA (Not Amplified n = 78) | Copy number of PIK3CA (Amplification n = 37) | P value |
|---|---|---|---|
| Age: mean ± SD |
64.8 ± 11.6 |
65.6 ± 9.9 |
0.60* |
| Sex: Male/Female |
63 / 15 |
30 / 7 |
0.96† |
| Number of metastatic |
|
|
|
| Lymph nodes: |
0/0/1.5 |
0/0/0 |
0.65‡ |
| 25%/50%/75% | |||
| Primary site |
|
|
0.39† |
| Oropharyngeal |
15(19.2%) |
10(27.0%) |
|
| Hypopharyngeal |
16(20.5%) |
9(24.3%) |
|
| Laryngeal |
15(19.2%) |
8(21.6%) |
|
| Oral cavity |
22(28.2%) |
9(24.3%) |
|
| Nasal cavity |
10(12.8%) |
1(2.7%) |
|
| Tumor grade: |
28/35/15 |
18/12/7 |
0.37† |
| well/ moderate/poor |
(35.9%/44.9%/19.2%) |
(48.6%/32.4%/18.9%) |
|
| TNM classification |
|
|
|
| T stage: T1/T2/T3/T4 |
12/30/17/19 |
4/15/10/8 |
0.85† |
| (15.3%/38.5%/21.8%/24.4%) |
(10.8%/40.5%/ 27.0%/21.6%) |
||
| N stage: N0/N1/N2 |
43/12/23 |
16/5/16 |
0.34† |
| (55.1%/15.4%/29.5%) |
(43.2%/13.5%/43.2%) |
||
| Stage : I/ II/III/IV |
11/16/17/34 |
1/7/9/20 |
0.28† |
| (14.1%/20.5%/21.8%/43.6%) |
(2.7%/18.9%/ 24.3%/54.1%) |
||
| Pack-year(tobacco) mean ± SD | 19.6 ± 24.3 | 22.3 ± 24.6 | 0.64* |
* Student t test † Chi-square test ‡ Fisher test.
The patients’ characteristics stratified by the PIK3CA copy number alteration. There was no significant association.